[摘要]:The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics. To lay groundwork for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we u